Publication not explained
This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.
If you are one of the authors, claim this publication so you can create a plain language summary to help more people find, understand and use it.
Featured Image
Read the Original
This page is a summary of: Clinical and economic impact of the 21-gene recurrence score assay in adjuvant therapy decision making in patients with early-stage breast cancer: pooled analysis in 4 Basque Country university hospitals, ClinicoEconomics and Outcomes Research, March 2018, Dove Medical Press,
DOI: 10.2147/ceor.s146095.
You can read the full text:
Contributors
The following have contributed to this page
